M. Cavallini, M. PapagniSkin hydration testN. patients 14SexFPre 62.06Post 74.00Difference 11.94Diff % 14.69Skin elasticity testN. patients 14SexFPre 17.69Post 14.81Difference 2.88Diff % 21.78Table 2. Patients evaluation with digital skin measurement system (Callegari Soft 5.5). Evaluations have been recorded before(pre) and one month later the end of treatment (post).The results are also supported by a digital skinmeasurement system obtained with pre andpost-treatment registration of hydration, sebometry,pH and elasticity. 14 female patients havebeen studied, mean age 38 years (min 22, max48). All the patients were submitted to the “preventive”cycle of treatment, with 3 sessions ofinjections with polynucleotides. The evaluationshave been recorded before and one monthafter the end of the treatment. The resultsshowed no interesting changes in pH parametersand sebometry; instead they showed satisf a c t o ry results about the of hydration(+14.7%), and the interesting increase of elasticitywith an improvement of 21.8% (Table 2,Figure 3) in accord with the action of stimulationof secretion of collagenic and non collagenicproteins by fibroblasts, due to the activity oflong polynucleotide molecules.The data obtained till now with this device areindicative of an important action on the skin bymacromolecular polynucleotides but a greaternumber of cases are necessary to confirm theseresults. However, this clinical ex<strong>per</strong>ience, besidesstill in progress, confirms objectively whatis found in subjective way both from patientsand physicians with the use of this product.There were no cases of severe side effects due tothe product used in the study. The injectionsare very well tolerated and do not cause muchpain. To achieve a most atraumatic injection itis recommended to change the needle duringmore extensive interventions, two 30G sterileneedles are provided with each syringe for betterpatient’s compliance. In sensitive patients itis possible to apply a local anaesthetic cream,but often during following treatments also sensitivepatients do not require the use of the localanaesthetic cream.Eyes skin-surrounding areas must be treatedcautiously because haematoma can develop followingany kind of infiltration pro c e d u re s .Slight erithema or a modest oedema in the treatedareas are rarely observed.The injected material spreads quickly and inmost cases it disappears after few hours.Sometimes, in particular thin areas like neckand eyes surrounding, after su<strong>per</strong>ficial andgreat micro wheals injections it is possible tohave the <strong>per</strong>sistence of micro wheals between 6and 36 hours.C ommentsThe use of long chain polynucleotidesin anti aging treatments to achieve orthodermyderives from more than 50 years of ex<strong>per</strong>ienceson polynucleotides mainly focused on woundhealing. Polynucleotides are considered to beimportant biostimulating agents for their actionon many different cells type among which dermalfibroblasts, as attested by the long list ofinternational bibliographic references on theiruse. Many studies show that nucleotides andnucleosides stimulate cell growth (9, 10) andwound healing (11, 12). In various in vitro studiespolynucleotides show trophic action onhuman fibroblasts in primary cultures and stimulatethe secretion activity of collagen proteinsand of other proteins of the extra cellularmatrix (13). Moreover clinical ex<strong>per</strong>iences inaesthetic medicine with polynucleotides mainlyfocused on skin biorevitalization (14-16), correctionof depressed scars (17-18) and striaedistensae (19-21).The new long chain polynucleotide gel formulationis specifically designed for aestheticmedicine biorevitalizing treatments. These particularpolynucleotides are characterized byhigh water binding capacity and viscoelasticity.Intra-dermal infiltrations can build up the extracellular matrix, with a prompt increase in skinelasticity, tone and turgor. Another benefit is30Journal of Plastic Dermatology <strong>2007</strong>; 3, 3
Long chain polynucleotides gel and skin biorevitalizationachieved by the free radicals scavenging pro<strong>per</strong>tiesof macromolecular polynucleotides. Duringthe polynucleotides biodegradation due toenzymes located in the extra cellular space (22,23), many metabolites are produced and availableto increase the protective action against freeradicals (24). Moreover, in vitro studies on UVBirradiated fibroblasts (25), and in vivo trials onhealthy volunteers (26), confirmed the protectiveaction carried out by polynucleotides againstsun damages.Prolonged iso-osmotic hydration and anti-radicalsaction contribute to recreate the mostfavourable physiological conditions in the dermalmatrix that stimulate fibroblast metabolicactivity and regeneration. By optimising theirvitality and secretion activity, autologous fibroblastscan restore the balance of the derma, andparticularly all the different elements composingeither the amorphous matrix (like glucosaminoglycans,glicoproteins, fibronectin) or thefibrillary matrix (collagen, elastic and reticularfibrils), therefore accomplishing a virtuous circlethat ensure long lasting bio-re v i t a l i z i n geffects of Plinest ® .Plinest ® can be used both like a single antiagingtherapy to give an improvement of the qualityof the skin and like a preparing treatment forother medical and surgical procedures (likelaser, chemical peeling, radiofrequency, surgery).In fact the increase of collagenic and noncollagenic substances in the dermis gives betterconditions in the results obtained with othertechniques for the better responses and reductionsof side effects. Protocols of treatment areparticularly suitable to light and moderate agingand photo aging cases, to thin and dry skin, toprevent skin aging and sun damage, to preparethe skin before sun exposure. Plinest ® can beadministered in an integrated manner withother rejuvenating treatments. Especially theskin biorevitalization before dermal fillerimplantation, peeling, laser treatment improveand extend the effect of the treatment done.Protocols of treatment can be used also to preparethe skin before aesthetic surgery procedureslike mini-lifting, lifting or blefaroplasty etc(15). There are also many other clinical ex<strong>per</strong>ienceson the use, in the last two years, of longchain polynucleotide gel in the treatment ofaging skin, particularly of the face, neck anddécolleté, the back of the hands (27, 28), and inpresence of skin dystrophy like striae distensae(29) confirming the results obtained in this clinicalstudy.C onclusionThe use of heterologous substances inaesthetic medicine can provide a temporaryvolumetric increase of the tissues, without anyspecific metabolic action on fibroblast. Instead,modern substances used in biorevitalization aredesigned to promote an increase on fibroblasts’number and metabolic activity and long chainpolynucleotides are considered to be importantbiostimulating agents for their specific actionon fibroblasts. In conclusion the product instudy helps the skin’s own cells to combat theeffect of aging because fibroblasts produce thenecessary collagenic and non collagenic moleculesto revitalize those areas of the face or bodythat show unwanted signs of aging. This in turncan improve the elasticity and general texture ofthe skin, giving a more youthful appearance.The results of the study are very satisfactoryalso because the product is easy to use, has thepatients’ compliance, with no significant sideeffects known so far.Figure 3. Percentage of post-treatment improvementof hydration and elasticity.R eferences1. Ebling FJ. Physiological background to skinageing. Int J Cosmet Sci 1982; 4:103-1102. Kligman AM, Lavker RM. Cutaneous Aging: the differencesbetween intrinsic aging. J Cutan Ageing CosmetolDermatol 1988; 1:5-123. Rook, Wilkinson, Ebling. Textbook of Dermatology –Sixth Edition, Blackwell Science, Biology of ageing 1998;chapter 74:3277-824. Cavallini M. Plinest: l’evoluzione della ricerca nella biorivitalizzazione.Medical Symposia J.Medical Books 2005;IX:1-4Journal of Plastic Dermatology <strong>2007</strong>; 3, 331
- Page 1: Vol. 3, n. 3, September-December 20
- Page 4: L’istopatologia ed il foto-invecc
- Page 10: P. Filecciaammesso nelle formulazio
- Page 13 and 14: A. Sparavigna A, R. Forte, F.S. Dio
- Page 15 and 16: A. Sparavigna A, R. Forte, F.S. Dio
- Page 17 and 18: A. Sparavigna A, R. Forte, F.S. Dio
- Page 20 and 21: M. Cavallini, M. Papagnitaining lon
- Page 24 and 25: M. Cavallini, M. Papagni5. Altman D
- Page 26 and 27: G. Menchini, C. ComacchiM ethodsO b
- Page 28 and 29: G. Menchini, C. Comacchimentation,
- Page 30 and 31: Impiego di lamine autoadesivedi pol
- Page 32 and 33: Impiego di lamine autoadesive di po
- Page 34 and 35: Impiego di lamine autoadesive di po
- Page 36 and 37: Efficacia, tollerabilità ed accett
- Page 38 and 39: Efficacia, tollerabilità ed accett
- Page 40 and 41: Efficacia, tollerabilità ed accett
- Page 42 and 43: D. AnconaGli studi sulla citotossic
- Page 44 and 45: D. AnconaPRIMADOPOFigura 2. Pazient
- Page 46 and 47: L.Scuderi, L. Francesconi, F. Dinot
- Page 48 and 49: L.Scuderi, L. Francesconi, F. Dinot
- Page 50 and 51: E. Perosino12Figura 1.Lesione macul
- Page 52 and 53: Irsutismo:trattamento con eflorniti
- Page 54 and 55: Irsutismo: trattamento con eflornit
- Page 56 and 57: Irsutismo: trattamento con eflornit
- Page 58 and 59: Irsutismo: trattamento con eflornit
- Page 60 and 61: Irsutismo: trattamento con eflornit
- Page 62 and 63: Irsutismo: trattamento con eflornit
- Page 64 and 65: Una molecola classicain una nuova v
- Page 66 and 67: Microcircolo, cute e antocianosidiA
- Page 68 and 69: Microcircolo, cute e antocianosidiL
- Page 70 and 71: Microcircolo, cute e antocianosidiG
- Page 72 and 73:
Microcircolo, cute e antocianosidiC
- Page 78:
struzioni agli AutoriIObiettivo del